Shots:

• Advent and GIC to acquire Sobi for ~$8B (SEK 69.4B) at $27.33/share (SEK 235) representing a premium of 34.5% to the closing price of $20.41. The offer acceptance period is expected to start on Sept 2021 and expire on Oct 21- 2021
• Sobi focuses on delivering innovative therapies and services in the areas of hematology- immunology- and specialty care & had a portfolio of 6 products & offices in ~ 30 countries- offering therapies for patients in ~ 70 countries
• Agnafit Bidco will obtain ownership of 90% of the total number of Shobi’s shares & the receipt of all necessary regulatory- governmental- or similar clearances- approvals & decisions- including from competition authorities

| Ref: Sobi | Image: Sobi